OSE Immunotherapeutics - Pipeline momentum builds into FY24
OSE Immunotherapeutics’ (OSE’s) FY23 update summarised an active period for its clinical pipeline that was capped by the post-period $713m deal...
396 Views
OSE Immunotherapeutics - One step closer to key data readouts
OSE Immunotherapeutics has announced the completion of patient enrolment in its Phase II CoTikiS trial, marking another step in the clinical...
393 Views
OSE Immunotherapeutics - Confidence boost with AbbVie partnership
OSE Immunotherapeutics has announced a global licence and collaboration agreement with AbbVie to develop OSE-230, a novel monoclonal antibody, for...
258 Views
OSE Immunotherapeutics - Encouraging OSE-279 clinical update
At the 2024 ESMO Targeted Anticancer Therapies Congress, OSE Immunotherapeutics (OSE) presented encouraging interim results from the Phase I/II...
285 Views
OSE Immunotherapeutics - Active year ahead for proprietary programmes
OSE has refreshed its outlook for 2024, including the commencement of the confirmatory Phase III trial for lead asset Tedopi (an off-the-shelf,...
267 Views